No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 7, 1995, Pages 850-855

  Moliterno, David J ^a   Jokinen, Eero V ^b   Miserez, André R ^b   Lange, Richard A ^b   Willard, John E ^b   Boerwinkle, Eric ^b,d   Hillis, L David ^b   Hobbs, Helen H ^b,c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d AMERICAN HEART ASSOCIATION   (United States)

Author keywords

African Americans; lipoprotein(a); plasminogen

Indexed keywords

LIPOPROTEIN A;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE SEQUENCE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; TANDEM REPEAT;

EID: 0029019338     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.15.7.850     Document Type: Article

References (55)

1. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246: 904-910.
2. Liu A, Lawn RM. Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med. 1994;4:40-44.
3. Lackner C, Boerwinkle E, Leffert C, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87: 2077-2086.
4. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
5. Albers JJ, Marcovina SM, Lodge MS. The unique lipoprotein(a): properties and immunochemical measurement. Clin Chem. 1990; 36:2019-2026.
6. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
7. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992;89:1040-1046.
8. Rhoads GG, Dahlèn GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
9. Dahlèn GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
10. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis. 1986;62: 249-257.
11. Guyton JR, Dahlèn GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272.
12. Parra H, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;167:27-31.
13. Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D, Armstrong VW. Contribution of the apo(a) phenotype to plasma Lp(a) concentrations shows considerable ethnic variation. J Lipid Res. 1991;32:1919-1928.
14. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups, evidence for no common "null" allele at the apo(a) locus. J Clin Invest. 1994;93:2526-2534.
15. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol. 1992;136:441-449.
16. Heyden S, Eckardstein AV, Schulte H, Schneider K, Assmann G. Raised lipoprotein(a) in hypercholesterolemic black students compared to age-matched whites in North and South Carolina. Int J Epidemiol. 1994;23:301-306.
17. Marcovina SM, Albers JJ, Jacobs DR Jr, Perkins LL, Lewis CE, Howard BV, Savage P. Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: the CARDIA study. Arterioscter Thromb. 1993;13:1037-1045.
18. National Center for Health Statistics. Vital and Health Statistics, No. 181. Hyattsville, MD: US Dept of Health and Human Services; 1990. DHHS Pub No. (PHS) 92-1509.
19. Kautz JA, Bradshaw BA, Fonner E Jr. Trends in cardiovascular mortality in Spanish-surnamed, other white, and black persons in Texas, 1970-1975. Circulation. 1981;64:730-735.
20. Gillum RF. Coronary heart disease in black populations, I: mortality and morbidity. Am Heart J. 1982;104:839-851.
21. Cassel J, Heyden S, Bartel AG. Incidence of coronary heart disease by ethnic group, social class, and sex. Arch Intern Med. 1971;128: 901-906.
22. Keil JE, Sutherland SE, Knapp RG, Lackland DT, Gazes PC, Tyroler HA. Mortality rates and risk factors from coronary disease in black as compared with white men and women. N Engl J Med. 1993;329:73-78.
23. Sorrentino MJ, Vielhauer C, Eisenbart JD, Fless GM, Scanu AM, Feldman T. Plasma lipoprotein(a) concentration and coronary artery disease in black patients compared with white patients. Am J Med. 1992;93:658-662.
24. Lipid Research Clinics Program. Lipid and Lipoprotein Analysis: Manual of Laboratory Operations. Washington, DC: US Dept of Health, Education, and Welfare; 1982. Pub. No. NIH/75-628.
25. Menzel HJ, Dieplinger H, Lackner C, Hoppichler F, Lloyd JK, Muller DR, Labeur C, Talmud PJ, Utermann G. Abetalipoproteinemia with an apoB-100-lipoprotein(a) glycoprotein complex in plasma. J Biol Chem. 1990;265:981-986.
26. Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet. 1991;49: 1063-1074.
27. Lackner C, Cohen J, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993;2:933-940.
28. Conover WJ. Practical Non-Parametric Statistics. New York, NY: John Wiley & Sons, Inc; 1980:215-237.
29. Guo WS, Thompson EA. Monte Carlo Estimation of P-Values for Sparse Contingency Tables: Technical Report #187. Seattle, Wash: University of Washington; 1987.
30. Noether GE. Sample size determination for some common nonparametric tests. J Am Stat Assoc. 1987;82:645-647.
31. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989:106-112.
32. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
33. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis. 1982;44:61-71.
34. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313-1319.
35. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci U S A. 1989;86:4171-4174.
36. Srinivasan SR, Frerichs RR, Webber LS, Berenson GS. Serum lipoprotein profile in children from a biracial community: the Bogalusa Heart Study. Circulation. 1976;54:309-318.
37. Srinivasan SR, Dahlèn GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Circulation. 1991;84:160-167.
38. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Shaefer EJ. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: The Framingham Offspring Study. Circulation. 1993;87:1135-1141.
39. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 1991;37:1950-1954.
40. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. J Clin Invest. 1992;89:1166-1171.
41. Soma M, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett J, Meschia M, Crosignani P. The lowering of lipoprotein(a) by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993;153:1462-1468.
42. Nabulsi A, Folsom A, White A, Patsch W, Heiss G, Wu K, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk faclors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
43. Tyroler HA, Heiss G, Schonfeld G, Cooper G, Heyden S, Hames CG. Apolipoprotein A-I, A-II, and C-II in African American and Caucasian residents of Evans County. Circulation. 1980;62:249-254.
44. Morrison JA, de Groot I, Kelly KA, Mellies MJ, Khoury P, Edwards BK, Lewis D, Lewis A, Fiorelli M, Heiss G, Tyroler HA, Glueck CJ. Black-white differences in plasma lipids and lipoproteins in adults: the Cincinnati Lipid Research Clinic population study. Prev Med. 1979;8:34-39.
45. Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates ER, Stack RS, Califf RM. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group: racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Circulation. 1991; 83:170-175.
46. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993;191:1192-1196.
47. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thomson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and lipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990; 322:1494-1499.
48. Abe A, Noma A, Lee YJ, Yamaguchi H. Studies on apolipoprotein(a) phenotypes, part 2: phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiograpically defined coronary artery disease. Atherosclerosis. 1992;96:9-15.
49. Rosengran A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990;301:1248-1251.
50. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen risk incidence and prevalence study (GRIPS). Eur J Clin Invest. 1994,24:444-453.
51. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA. 1994;271; 999-1003.
52. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-2199.
53. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
54. Alfthan G, Pekkanen J, Jauhiainen M, Karvonen M, Tuoilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994; 106:9-19.
55. Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-1025.